LOS ANGELES -- When Mike Godfrey's employer, Scripps Health in La Jolla, Calif., put out a call for recruits for a study on genetic testing, the communications executive hesitated before volunteering to hand over a swab of his saliva.
He wasn't completely sure he wanted to know what the test would reveal about diseases he might get down the road.
Thinking twice made sense. Ever since the 2007 introduction of direct-to-consumer genomewide tests -- which scan a person's DNA and report on the genetic risk of developing 20 to 40 common diseases -- experts have wondered if telling regular folks they're more likely to develop illnesses such as diabetes, heart disease or cancer would trigger extreme anxiety, or would result in increased use of unnecessary and expensive medical tests.
Apparently it does not, the Scripps study found.